B of A Securities Maintains Buy on Agios Pharmaceuticals, Lowers Price Target to $40
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $41 to $40.
B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target from $41 to $40.